Rep. Brendan Boyle Tour of Genomind Lab In King of Prussia to Showcase Personalized Medicine for Mental Health

July 13, 2016

Rep. Brendan Boyle Tour of Genomind Lab In King of Prussia to Showcase Personalized Medicine for Mental Health

July 13, 2016

Rep. Brendan Boyle Tour of Genomind Lab In King of Prussia to Showcase Personalized Medicine for Mental Health

KING OF PRUSSIA, PA.– July 13, 2016– Genomind (www.genomind.com), a personalized medicine company bringing innovation to mental health care, will highlight the importance of the biotech industry to Pennsylvania when Representative Brendan Boyle tours its lab.

Wednesday, July 20 from 10–11 a.m., Rep. Boyle, who represents Pennsylvania’s 13th Congressional District, will visit the company’s CLIA certified laboratory at 2200 Renaissance Blvd, Suite 100, King of Prussia, PA. The facility is where Genomind performs its genetic testing that can help guide clinicians as to which mental health treatments are likely to work as intended, have no effect or cause adverse effects.

Genomind is also proud to announce it has reached an important milestone: the 80,000th patient has received results from the company’s Genecept Assay®, its genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It is an easily administered cheek swab test that analyzes key genes, selected based on the critical examination of hundreds of studies showing that variations in these genes can inform treatment decisions in psychiatry.

Rep. Boyle will be joined on the lab tour by Christopher Molineaux, the President and CEO of Pennsylvania Bio (www.pabio.org), which works to ensure Pennsylvania is the nation’s hub for the life sciences by creating a business and public policy environment which fosters life sciences growth and success.

“Genomind is a shining example of the strength of the life sciences industry in Pennsylvania. The tour with Congressman Boyle will be an important opportunity to showcase the groundbreaking work Genomind is doing and how it greatly contributes to our economy,” says Molineaux.

Recent research found 87 percent of patients demonstrated a clinically measurable improvement with treatment guided by Genecept. It also reported improvement in 91 percent of patients who had failed at least two medications in the past: https://genomind.com/clinical-evidence/.

The Genecept Assay is available for use by any licensed and prescribing clinician. Patients should discuss with their clinician whether Genecept is right for them https://genomind.com/talk-to-your-doctor/. Patients should have their clinician contact Genomind directly to order test kits and/or to receive more information about testing.

###

About Genomind

Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.

About the Genecept Assay®

The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at www.genomind.com.